OpenEvidence: $12B valuation, IPO Readiness 52, Series B. OpenEvidence is an AI-powered clinical assistant that helps physicians instantly access synthesized medical ev. Track live on The IPO Stack.
OpenEvidence is an AI-powered clinical assistant that helps physicians instantly access synthesized medical evidence to make better patient care decisions at the point of care.
Scores, valuations, and IPO signals for the companies that matter. 5-minute read, every Tuesday.
Top companies most likely to IPO in 2026, ranked by IPO Readiness Score.
Track OpenEvidence IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO — the pre-IPO intelligence platform.
OpenEvidence has not announced a specific IPO date as of 2026. Track TechStackIPO for the latest funding milestones and IPO signals. Subscribe to The IPO Stack newsletter for weekly updates.
OpenEvidence is valued at $12B as of the most recent funding round. This valuation is based on its most recent private funding round tracked by TechStackIPO.
Accredited investors can access OpenEvidence shares through secondary market platforms, pre-IPO investment funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace tracks available access options. Note: pre-IPO investments carry higher risk and limited liquidity compared to public market investing.
OpenEvidence scores 52/100 (Grade: D) on TechStackIPO's IPO Readiness Index. The score evaluates funding scale, valuation trajectory, funding momentum, stage progression, and company maturity. Scores above 70 indicate strong near-term IPO potential.
OpenEvidence's notable investors include Index Ventures. Full investor details, funding round history, and lead investor breakdowns are available on TechStackIPO.
OpenEvidence is a Healthcare Technology company. OpenEvidence is an AI-powered clinical assistant that helps physicians instantly access synthesized medical evidence to .